C1q Deficiency Leads to the Defective Suppression of IFN-α in Response to Nucleoprotein Containing Immune Complexes
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Almost all humans with homozygous deficiency of C1q develop systemic lupus erythematosus (SLE). The precise cellular mechanism(s) by which C1q prevents the development of SLE remains unclear. In this study, we tested the role of C1q in the regulation of IFN-α induced by immune complexes (ICs) in vitro, as well as the consequences of lack of C1q in vivo. Our experiments revealed that C1q preferentially promotes the binding of SLE ICs to monocytes rather than plasmacytoid dendritic cells, but this inhibition was not due to the induction of inhibitory soluble factors. The presence of C1q also altered the trafficking of ICs within monocytes such that ICs persisted in early endosomes. In patients with C1q deficiency, serum and cerebrospinal fluid levels of IFN-α and IFN-γ–inducible protein-10 levels were elevated and strongly correlated with Ro autoantibodies, demonstrating the clinical significance of these observations. These studies therefore associate C1q deficiency with defective regulation of IFN-α and provide a better understanding of the cellular mechanisms by which C1q prevents the development of IC-stimulated autoimmunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1982 revised criteria for the classification of systemic lupus erythematosus
Tan, E. M., Cohen, A. S., Fries, J. F., Masi, A. T., Mcshane, D. J., Rothfield, N. F., Schaller, J. G., Talal, N., & Winchester, R. J. (1982) · Arthritis & Rheumatism · doi:10.1002/art.1780251101 · Cited by 14,519
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
Botto, M., Dell' Agnola, C., Bygrave, A. E., Thompson, E. M., Cook, H. T., Petry, F., Loos, M., Pandolfi, P. P., & Walport, M. J. (1998) · Nature Genetics · doi:10.1038/ng0598-56 · Cited by 1,434 · cited 1×
“The early classical complement proteins, C1q, C2, and C4, may act in a common pathway leading to the assembly of C3bi on apoptotic cells, which we, and others, previously showed is important for the clearance of dying cells (70, 71).”
BackgroundRepeat-induced gene silencing in mammals
Garrick, D., Fiering, S., Martin, D. I. K., & Whitelaw, E. (1998) · Nature Genetics · doi:10.1038/ng0198-56 · Cited by 887
The Role of Complement in the Development of Systemic Lupus Erythematosus
Manderson, A. P., Botto, M., & Walport, M. J. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104549 · Cited by 538
Cited by
Kaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Aicardi–Goutières syndrome and the type I interferonopathies
Crow, Y. J., & Manel, N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3850 · Cited by 925
Recognition of Endogenous Nucleic Acids by the Innate Immune System
Roers, A., Hiller, B., & Hornung, V. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.002 · Cited by 541
Kahlenberg, J. M., Carmona-Rivera, C., Smith, C. K., & Kaplan, M. J. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202388 · Cited by 508
The type I interferonopathies: 10 years on
Crow, Y. J., & Stetson, D. B. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00633-9 · Cited by 489
Rodero, M. P., & Crow, Y. J. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20161596 · Cited by 433
Type I interferonopathies: a novel set of inborn errors of immunity
Crow, Y. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06220.x · Cited by 404
Complement, C1q, and C1q-Related Molecules Regulate Macrophage Polarization
Bohlson, S. S., O’Conner, S. D., Hulsebus, H. J., Ho, M.-M., & Fraser, D. A. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00402 · Cited by 297
The interferon signature in autoimmune diseases
Rönnblom, L., & Eloranta, M.-L. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32835c7e32 · Cited by 294
Briggs, T. A., Rice, G. I., Daly, S., Urquhart, J., Gornall, H., Bader-Meunier, B., Baskar, K., Baskar, S., Baudouin, V., Beresford, M. W., et al. (2011) · Nature Genetics · doi:10.1038/ng.748 · Cited by 261
Self-citationC1q: A fresh look upon an old molecule
Thielens, N. M., Tedesco, F., Bohlson, S. S., Gaboriaud, C., & Tenner, A. J. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.05.025 · Cited by 237
“…shifted IC binding to monocytes and away from plasmacytoid DCs (pDCs), thereby reducing the expression of the majority of IFNα-response genes induced by ICs (Santer et al., 2010; Santer et al., 2012) and characteristic of the IFN signature associated with SLE progression (Baechler et al., 2003).”
BackgroundC1q limits dendritic cell differentiation and activation by engaging LAIR-1
Son, M., Santiago-Schwarz, F., Al-Abed, Y., & Diamond, B. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1212753109 · Cited by 179
“Genetic C1q deficiency represents the strongest susceptibility factor contributing to the development of SLE (5).”
BackgroundInfluentialColonna, L., Lood, C., & Elkon, K. B. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000083 · Cited by 69
Self-citationAutoantibodies against complement component C1q in systemic lupus erythematosus
Trendelenburg, M. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1279 · Cited by 48
Anti-DNA antibodies cross-react with C1q
Franchin, G., Son, M., Kim, S. J., Ben-Zvi, I., Zhang, J., & Diamond, B. (2013) · Journal of Autoimmunity · doi:10.1016/j.jaut.2013.06.002 · Cited by 41
Metadata
- Authors
- Santer, D. M., Hall, B. E., George, T. C., Tangsombatvisit, S., Liu, C. L., Arkwright, P. D., & Elkon, K. B.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-10
- Volume
- 185
- Issue
- 8
- Pages
- 4738-4749
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1852489937
- Cited by
- 150
- References
- 4
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.